Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01788189
Other study ID # EudraCT No. 2012-001891-13
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 2013
Est. completion date February 20, 2020

Study information

Verified date February 2020
Source University Hospital, Essen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter prospective open-label non-randomised phase I/II study in patients with relapsed or refractory CD20-positive aggressive lymphomas

Phase I:

Dose escalation of methotrexate and cytarabine (days 1, 8 and 15 of each 28-day cycle) in a 3 + 3 design with fixed doses of lenalidomide (days 1 - 21) and rituximab (day 1), maximum 6 cycles

Phase II:

Treatment of 20 patients at maximum tolerated doses of phase I


Description:

Phase I

The goal of the phase I part of the study is to determine the maximum tolerated doses of methotrexate and cytarabine able to be combined with once-per-cycle rituximab and full-dose 3-weeks-on/1-week-off lenalidomide in 28-day treatment cycles. Methotrexate and cytarabine will be given three times per cycle, preferably on days 1, 8 and 15. If short-term toxicity precludes once-per-week dosing, treatment may be delayed by a maximum of 3 days, e.g. the second injection of methotrexate and cytarabine may be delayed until day 11 and the third injection until day 21. The doses of methotrexate and cytarabine will be adjusted to permit administration of three doses per cycle without the need to postpone the subsequent treatment cycle by more than 7 days.

Dose limiting toxicity will be determined by increasing the doses of methotrexate and cytarabine in sequential patient cohorts in a 3 + 3 design. Because tolerance to lenalidomide and cytotoxic agents are likely to decrease with increasing numbers of treatment cycles, evaluation of dose-limiting toxicity will be confined to the first two cycles. The requirement for dose reductions in subsequent treatment cycles will not be rated as dose-limiting toxicity.

If no dose-limiting toxicity is observed in 3 patients treated at the same dose level, the next 3 patients will be treated at the next higher dose level. If a single patient experiences dose-limiting toxicity, another 3 patients will be treated at the same dose level. If no more than one dose-limiting toxicity is observed in 6 patients treated at that level, the next 3 patients will be treated at the subsequent dose level. If two or more of 3 - 6 patients treated at the same level experience dose-limiting toxicity, dose escalation will be stopped. The dose level below the level where dose-limiting toxicity was observed defines the maximum tolerated dose.

The dose level below the level where dose-limiting toxicity is observed defines the maximum tolerated doses of methotrexate and cytarabine. However, if, at a lenalidomide dose of 25 mg, methotrexate and cytarabine cannot be escalated beyond the first dose level, the lenalidomide dose will be reduced to 20 mg, and the methotrexate/cytarabine dose level producing dose-limiting toxicity will be repeated at a lenalidomide dose of 20 mg. If, at a lenalidomide dose of 20 mg, methotrexate and cytarabine cannot be escalated beyond the first dose level, the lenalidomide dose will be reduced to 15 mg, and the methotrexate/cytarabine dose level producing dose-limiting toxicity will be repeated with a lenalidomide dose of 15 mg. If, at a lenalidomide dose of 15 mg, methotrexate and cytarabine cannot be escalated beyond the first dose level, dose limiting toxicity is reached and the maximum tolerated dose is the highest dose of lenalidomide able to be combined with the first dose level of methotrexate and cytarabine in a 3 + 3 phase I design.

The toxicity profiles of methotrexate (mucositis, hepatotoxicity) and cytarabine (hematotoxicity, hepatotoxicity) differ. In order to determine the maximum tolerated dose of each compound, further dose escalation of one or other drug may be required after the maximum tolerated dose of the methotrexate/cytarabine combination (as defined in dose levels 1 - 5, see below) has been determined. If dose-limiting hematotoxicity occurs without concomitant dose-limiting mucositis or hepatotoxicity, the dose of methotrexate may be escalated without concomitant increase of the cytarabine dose. Conversely, if severe mucositis occurs without concomitant dose-limiting hematotoxicity or hepatotoxicity, the dose of cytarabine may be escalated without concomitant increase of the methotrexate dose. Dose modifications of individual drugs will be made by the coordinating principal investigator according to the observed toxicities using the levels defined for the methotrexate/cytarabine combination.

Toxicities observed during the first two treatment cycles will be reported to the trial office within 7 days after their occurrence (in case of serious adverse events within 24 hours). Based on the predefined criteria listed below the coordinating principal investigator and the trial coordinator will decide whether or not a toxicity fulfils the requirements of a dose-limiting toxicity. After inclusion of up to 6 patients on the same dose level the coordinating principal investigator and the trial coordinator will decide according to the principles outlined in this protocol whether it is safe to move on to the next dose level. If rating a toxicity as dose-limiting is equivocal and/or no agreement is obtained between the coordinating principal investigator and the trial coordinator, the principal investigators of all participating trial sites will be included in the decision making process. Stepping-up to the next dose level will require more votes to be in favor of than against dose escalation.

Dose-limiting toxicities are:

- any of the following on the day of methotrexate/cytarabine injection (day 8 + ≤ 3 days / day 15 + ≤ 6 days of the first or second treatment cycle; day 1 of the second or third cycle which is equivalent to day 29 + ≤ 7 days of the previous cycle): neutrophils < 500/µl, platelets < 25.000/µl, creatinine clearance < 60 ml/min, bilirubin ≥ 3,0 mg/dl, serum AST/GOT or ALT/GPT ≥ 6 x upper limit of normal, mucositis grade 3 or 4

- requirement for dose reduction of methotrexate/cytarabine in the first or second treatment cycle

- fewer than 21 days of lenalidomide in the first or second treatment cycle

- toxicity-related delay of second or third treatment cycle by more than 7 days

- any other toxicity preventing continuation of therapy according to protocol in the first or second treatment cycle (except allergic reactions)

Depending on previous treatment history patients will vary in their tolerance to the LeMLAR regimen. To provide maximum therapeutic benefit, the doses of methotrexate and cytarabine will be escalated within individual patients after cycles 2 and 4 as detailed below provided no dose limiting toxicities occurred in previous treatment cycles. Dose escalation in cycles 3 to 6 in individual patients will not be used to determine dose-limiting toxicity. This will only be done in cycles 1 and 2.

Patients should receive 6 treatment cycles unless tumor progression, unacceptable toxicity or treatment intolerance occurs. Treatment intolerance includes physician or patient preference to discontinue or change treatment in a manner not compatible with the protocol. If treatment according to the LeMLAR protocol is prematurely stopped, its result must be documented by the procedures outlined in the protocol.

Definition of dose levels of methotrexate and cytarabine (cohorts of 3 - 6 patients):

Level 1

Cycles 1 - 2: methotrexate 30 mg/m², cytarabine 75 mg/m²; cycles 3 - 4: if no dose-limiting toxicity occurs in cycles 1 and 2: methotrexate 60 mg/m², cytarabine 150 mg/m²; cycles 5 - 6: if no dose-limiting toxicity occurs in cycles 3 and 4: methotrexate 90 mg/m², cytarabine 225 mg/m²

Level 2

Cycles 1 - 2: methotrexate 60 mg/m², cytarabine 150 mg/m²; cycles 3 - 4: if no dose-limiting toxicity occurs in cycles 1 and 2: methotrexate 90 mg/m², cytarabine 225 mg/m²; cycles 5 - 6: if no dose-limiting toxicity occurs in cycles 3 and 4: methotrexate 120 mg/m², cytarabine 300 mg/m²

Level 3

Cycles 1 - 2: methotrexate 90 mg/m², cytarabine 225 mg/m²; cycles 3 - 4: if no dose-limiting toxicity occurs in cycles 1 and 2: methotrexate 120 mg/m², cytarabine 300 mg/m²; cycles 5 - 6: if no dose-limiting toxicity occurs in cycles 3 and 4: methotrexate 150 mg/m², cytarabine 375 mg/m²

Level 4

Cycles 1 - 2: methotrexate 120 mg/m², cytarabine 300 mg/m²; cycles 3 - 6: if no dose-limiting toxicity occurs in cycles 1 and 2: methotrexate 150 mg/m², cytarabine 375 mg/m²

Level 5

Cycles 1 - 6: methotrexate 150 mg/m², cytarabine 375 mg/m²

Phase II

The results of the phase I part of the trial will be summarized and submitted as an interim report to Celgene. Initiation of phase II will require reliable data defining the maximum tolerated dose and demonstration of clinical activity in at least some of the patients treated in phase I.

A total of 20 evaluable patients will be treated at the maximum tolerated dose level. If in phase I three patients were treated at the maximum tolerated dose, another 15 will be added in phase II. If six patients were treated in phase I, another 12 will be included in phase II.

Patients in the phase II part will receive a maximum of 6 treatment cycles. If no dose-limiting toxicity occurs in the first two cycles, the doses of methotrexate and cytarabine may be escalated in cycles 3 and 4, and, in case of no toxicities in cycles 3 and 4, again in cycles 5 and 6. Treatment will be stopped prematurely in case of tumor progression, unacceptable toxicity, intolerance or physician or patient preference.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date February 20, 2020
Est. primary completion date February 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years

- Performance status ECOG 0 - 3

- First or subsequent relapse or refractoriness of a biopsy-proven CD20-positive aggressive B cell lymphoma (excluding mantle cell lymphoma)

- Measurable disease

- Ineligibility or unwillingness to undergo high-dose chemotherapy with autologous stem cell transplantation

- Ability to understand the aim of the study and act accordingly

- Effective contraception

- Signed informed consent

Exclusion Criteria:

- Central nervous system relapse of aggressive lymphoma

- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study

- Any condition including the presence of laboratory abnormalities which places the subject at unacceptable risk if he/she were to participate in the study

- Any condition that confounds the ability to interpret data from the study

- Inadequate organ function not related to aggressive lymphoma:

- neutrophils < 1.0/nl

- platelets < 75/nl

- creatinine clearance < 60 ml/min

- bilirubin = 2,5 mg/dl

- serum AST/GOT or ALT/GPT = 4 x upper limit of normal

- Active viral hepatitis (HBV, HCV), HIV infection, any other uncontrolled infection

- Pregnancy and nursing period

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lenalidomide


Locations

Country Name City State
Germany Klinik für Hämatologie, Universitätsklinikum Essen Essen

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Essen Celgene

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Relapse rate 1 year
Other Event-free survival 1 year
Other Disease-free survival 1 year
Other Overall survival 1 year
Other Toxicity (type, onset, duration) 1 year
Other Secondary malignancies 5 years
Other Complete remission rate Six months
Other Partial remission rate Six months
Other Rate of stable disease Six months
Other Rate of progressive disease Six months
Primary Dose-limiting toxicity Phase I:
Dose-limiting toxicity of the combination regimen, determination of the maximum tolerated doses of methotrexate and cytarabine
Phase II:
Overall response rate (percentage of complete and partial remissions combined)
Two months
Secondary Progression-free survival 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Withdrawn NCT05929716 - An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Recruiting NCT05016947 - Venetoclax Plus Inotuzumab for B-ALL Phase 1
Completed NCT02900716 - Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Phase 1
Completed NCT03068416 - CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy Phase 2
Not yet recruiting NCT05014100 - Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma Phase 2
Recruiting NCT05934838 - A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas Phase 1
Terminated NCT04023071 - FT516 in Subjects With Advanced Hematologic Malignancies Phase 1
Active, not recruiting NCT04148430 - A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy Phase 2
Completed NCT02933320 - BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia Phase 1/Phase 2
Active, not recruiting NCT03133221 - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Phase 2
Completed NCT02741388 - A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP Phase 1
Completed NCT02300402 - Detection and Characterization of Residual Masses in Lymphomas
Terminated NCT02266147 - Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma Phase 1/Phase 2
Terminated NCT00906841 - Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma Phase 2
Completed NCT00338494 - Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Phase 1
Recruiting NCT05487651 - Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies Phase 1
Withdrawn NCT05570188 - Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT03281551 - Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma Phase 1